By Taylor Mixides (Drug Target Review)2024-01-04T09:15:10
In this interview we discuss with Alder Therapeutics regenerative cell therapy development through a proactive strategy, addressing manufacturing challenges early and ensuring a streamlined process. We explore an approach in pluripotent stem cell therapy development which eliminates complexities, minimises costs and expedites the delivery of transformative therapies.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-07-10T09:00:00Z
2026-07-10T06:15:00Z
Contributor Professor Donald E Ingber, By Drug Target Review
2026-07-09T12:00:00Z
2026-07-08T12:00:00Z
2024-02-08T11:07:39
Sponsored by Samplix ApS
2025-04-02T14:00:00
Sponsored by Eurofins Discovery
2023-05-30T13:51:56
Sponsored by BPS Bioscience
2023-02-13T11:57:11
Sponsored by Agilent
Site powered by Webvision Cloud